Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas

R. Bettini, W. Mantovani, L. Boninsegna, S. Crippa, P. Capelli, C. Bassi, A. Scarpa, P. Pederzoli, M. Falconi

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: The role of debulking surgery in metastatic nonfunctioning pancreatic endocrine carcinomas (M-NF-PECs) with resectable primary tumour and unresectable liver metastases is debated. Aim: Aim of the study is to evaluate whether the resection of the primary tumour in metastatic nonfunctioning pancreatic endocrine carcinoma improves survival. Patients and methods: Fifty-one metastatic nonfunctioning pancreatic endocrine carcinoma patients with unresectable liver metastases were enrolled from 1990 to 2004 at the time of diagnosis. Nineteen patients underwent complete resection of the primary tumour whilst 32 were judged unresectable. All cases were classified according to the WHO 2000 classification. All clinico-pathological parameters, including grade of differentiation and the Ki-67 proliferation index were considered in univariate and multivariate models. Results: Of the 19 resected patients, 14 (73.7%) underwent left-pancreatectomy and 5 (26.3%) pancreaticoduodenectomy. In the unresected group of 32 patients, 9 (28.1%) underwent surgical biliary and/or gastric by-pass. There was no postoperative mortality and the median survival was 54.3 months (95% CI: 25.7-82.9). No difference in survival was observed between the two groups [resected: median 54.3 months (95% CI: 25-83.6), unresected: median 39.5 months (95% CI: 5.4-73.6); p = 0.74]. Upon multivariate analysis poor differentiation (HR 3.01; 95% CI 1.08-8.4; p = 0.035) and a Ki-67 index ≥10% (HR 4.4; 95% CI 1.2-16.1; p = 0.023) were significant predictors of survival. Conclusions: Resection of the primary pancreatic tumour in metastatic nonfunctioning pancreatic endocrine carcinoma patients with unresectable liver metastases does not significantly improve survival. Resection can be considered as symptomatic palliative therapy in patients with well-differentiated endocrine carcinomas and a proliferative index lower than 10%.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalDigestive and Liver Disease
Volume41
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Survival
Neoplasms
Neoplasm Metastasis
Liver
Pancreatectomy
Pancreaticoduodenectomy
Pancreatic Carcinoma
Palliative Care
Stomach
Multivariate Analysis
Carcinoma
Mortality

Keywords

  • Debulking
  • Endocrine pancreatic tumour
  • Pancreatic carcinoma
  • Surgical treatment

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. / Bettini, R.; Mantovani, W.; Boninsegna, L.; Crippa, S.; Capelli, P.; Bassi, C.; Scarpa, A.; Pederzoli, P.; Falconi, M.

In: Digestive and Liver Disease, Vol. 41, No. 1, 01.2009, p. 49-55.

Research output: Contribution to journalArticle

Bettini, R, Mantovani, W, Boninsegna, L, Crippa, S, Capelli, P, Bassi, C, Scarpa, A, Pederzoli, P & Falconi, M 2009, 'Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas', Digestive and Liver Disease, vol. 41, no. 1, pp. 49-55. https://doi.org/10.1016/j.dld.2008.03.015
Bettini, R. ; Mantovani, W. ; Boninsegna, L. ; Crippa, S. ; Capelli, P. ; Bassi, C. ; Scarpa, A. ; Pederzoli, P. ; Falconi, M. / Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. In: Digestive and Liver Disease. 2009 ; Vol. 41, No. 1. pp. 49-55.
@article{ae968b29c60244e28d44fe2bec61714c,
title = "Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas",
abstract = "Background: The role of debulking surgery in metastatic nonfunctioning pancreatic endocrine carcinomas (M-NF-PECs) with resectable primary tumour and unresectable liver metastases is debated. Aim: Aim of the study is to evaluate whether the resection of the primary tumour in metastatic nonfunctioning pancreatic endocrine carcinoma improves survival. Patients and methods: Fifty-one metastatic nonfunctioning pancreatic endocrine carcinoma patients with unresectable liver metastases were enrolled from 1990 to 2004 at the time of diagnosis. Nineteen patients underwent complete resection of the primary tumour whilst 32 were judged unresectable. All cases were classified according to the WHO 2000 classification. All clinico-pathological parameters, including grade of differentiation and the Ki-67 proliferation index were considered in univariate and multivariate models. Results: Of the 19 resected patients, 14 (73.7{\%}) underwent left-pancreatectomy and 5 (26.3{\%}) pancreaticoduodenectomy. In the unresected group of 32 patients, 9 (28.1{\%}) underwent surgical biliary and/or gastric by-pass. There was no postoperative mortality and the median survival was 54.3 months (95{\%} CI: 25.7-82.9). No difference in survival was observed between the two groups [resected: median 54.3 months (95{\%} CI: 25-83.6), unresected: median 39.5 months (95{\%} CI: 5.4-73.6); p = 0.74]. Upon multivariate analysis poor differentiation (HR 3.01; 95{\%} CI 1.08-8.4; p = 0.035) and a Ki-67 index ≥10{\%} (HR 4.4; 95{\%} CI 1.2-16.1; p = 0.023) were significant predictors of survival. Conclusions: Resection of the primary pancreatic tumour in metastatic nonfunctioning pancreatic endocrine carcinoma patients with unresectable liver metastases does not significantly improve survival. Resection can be considered as symptomatic palliative therapy in patients with well-differentiated endocrine carcinomas and a proliferative index lower than 10{\%}.",
keywords = "Debulking, Endocrine pancreatic tumour, Pancreatic carcinoma, Surgical treatment",
author = "R. Bettini and W. Mantovani and L. Boninsegna and S. Crippa and P. Capelli and C. Bassi and A. Scarpa and P. Pederzoli and M. Falconi",
year = "2009",
month = "1",
doi = "10.1016/j.dld.2008.03.015",
language = "English",
volume = "41",
pages = "49--55",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "1",

}

TY - JOUR

T1 - Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas

AU - Bettini, R.

AU - Mantovani, W.

AU - Boninsegna, L.

AU - Crippa, S.

AU - Capelli, P.

AU - Bassi, C.

AU - Scarpa, A.

AU - Pederzoli, P.

AU - Falconi, M.

PY - 2009/1

Y1 - 2009/1

N2 - Background: The role of debulking surgery in metastatic nonfunctioning pancreatic endocrine carcinomas (M-NF-PECs) with resectable primary tumour and unresectable liver metastases is debated. Aim: Aim of the study is to evaluate whether the resection of the primary tumour in metastatic nonfunctioning pancreatic endocrine carcinoma improves survival. Patients and methods: Fifty-one metastatic nonfunctioning pancreatic endocrine carcinoma patients with unresectable liver metastases were enrolled from 1990 to 2004 at the time of diagnosis. Nineteen patients underwent complete resection of the primary tumour whilst 32 were judged unresectable. All cases were classified according to the WHO 2000 classification. All clinico-pathological parameters, including grade of differentiation and the Ki-67 proliferation index were considered in univariate and multivariate models. Results: Of the 19 resected patients, 14 (73.7%) underwent left-pancreatectomy and 5 (26.3%) pancreaticoduodenectomy. In the unresected group of 32 patients, 9 (28.1%) underwent surgical biliary and/or gastric by-pass. There was no postoperative mortality and the median survival was 54.3 months (95% CI: 25.7-82.9). No difference in survival was observed between the two groups [resected: median 54.3 months (95% CI: 25-83.6), unresected: median 39.5 months (95% CI: 5.4-73.6); p = 0.74]. Upon multivariate analysis poor differentiation (HR 3.01; 95% CI 1.08-8.4; p = 0.035) and a Ki-67 index ≥10% (HR 4.4; 95% CI 1.2-16.1; p = 0.023) were significant predictors of survival. Conclusions: Resection of the primary pancreatic tumour in metastatic nonfunctioning pancreatic endocrine carcinoma patients with unresectable liver metastases does not significantly improve survival. Resection can be considered as symptomatic palliative therapy in patients with well-differentiated endocrine carcinomas and a proliferative index lower than 10%.

AB - Background: The role of debulking surgery in metastatic nonfunctioning pancreatic endocrine carcinomas (M-NF-PECs) with resectable primary tumour and unresectable liver metastases is debated. Aim: Aim of the study is to evaluate whether the resection of the primary tumour in metastatic nonfunctioning pancreatic endocrine carcinoma improves survival. Patients and methods: Fifty-one metastatic nonfunctioning pancreatic endocrine carcinoma patients with unresectable liver metastases were enrolled from 1990 to 2004 at the time of diagnosis. Nineteen patients underwent complete resection of the primary tumour whilst 32 were judged unresectable. All cases were classified according to the WHO 2000 classification. All clinico-pathological parameters, including grade of differentiation and the Ki-67 proliferation index were considered in univariate and multivariate models. Results: Of the 19 resected patients, 14 (73.7%) underwent left-pancreatectomy and 5 (26.3%) pancreaticoduodenectomy. In the unresected group of 32 patients, 9 (28.1%) underwent surgical biliary and/or gastric by-pass. There was no postoperative mortality and the median survival was 54.3 months (95% CI: 25.7-82.9). No difference in survival was observed between the two groups [resected: median 54.3 months (95% CI: 25-83.6), unresected: median 39.5 months (95% CI: 5.4-73.6); p = 0.74]. Upon multivariate analysis poor differentiation (HR 3.01; 95% CI 1.08-8.4; p = 0.035) and a Ki-67 index ≥10% (HR 4.4; 95% CI 1.2-16.1; p = 0.023) were significant predictors of survival. Conclusions: Resection of the primary pancreatic tumour in metastatic nonfunctioning pancreatic endocrine carcinoma patients with unresectable liver metastases does not significantly improve survival. Resection can be considered as symptomatic palliative therapy in patients with well-differentiated endocrine carcinomas and a proliferative index lower than 10%.

KW - Debulking

KW - Endocrine pancreatic tumour

KW - Pancreatic carcinoma

KW - Surgical treatment

UR - http://www.scopus.com/inward/record.url?scp=57449103830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57449103830&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2008.03.015

DO - 10.1016/j.dld.2008.03.015

M3 - Article

C2 - 18463008

AN - SCOPUS:57449103830

VL - 41

SP - 49

EP - 55

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 1

ER -